Kenya

To assess the use of IPTp, the 2015 KMIS asked women who had a live birth in the 2 years
prior to the survey if they had taken SP or Fansidar, the brand name for SP, to prevent them from
getting malaria during pregnancy. Women reporting they had taken SP/Fansidar were asked how
many doses they had taken, and if they had received ANC services, they were asked if they received
the SP/Fansidar during an antenatal visit.
Tables 4.2 and 4.3 present the proportion of women who gave birth during the 2-year period
prior to the survey, and who received IPTp during the most recent pregnancy, according to the
number of SP doses they received (one or more, two or more, and three or more). For a woman to be
counted as having had IPTp, at least one of the doses of SP had to be received during an ANC visit.
Table 4.2 shows that nationally 51 percent of the women received one or more doses of IPTp, 35
percent received two or more doses, and 22 percent received at least three doses. Although IPTp is
not recommended outside of malaria-endemic areas, a substantial proportion of women in nonendemic
areas received IPTp during their recent pregnancies.
Table 4.2 Use of intermittent preventive treatment (IPTp) by women during pregnancy
Percentage of women age 15-49 with a live birth in the 2 years preceding the survey who,
during the pregnancy preceding the last birth, received one or more doses of SP/Fansidar at
least one of which was received during an ANC visit, received two or more doses of
SP/Fansidar at least one of which was received during an ANC visit, and received three or
more doses of SP/Fansidar at least one of which was received during an ANC visit, by
background characteristics, Kenya 2015
Background
characteristic
Percentage
who received 1
or more doses
of SP/Fansidar 1
Percentage
who received 2
or more doses
of SP/Fansidar 1
Percentage
who received 3
or more doses
of SP/Fansidar 1
Number of
women with a
live birth in the
2 years
preceding the
survey
Residence
Urban 49.6 34.5 22.0 419
Rural 51.3 34.8 21.9 849
Malaria endemicity
Highland epidemic 45.4 30.7 20.3 285
Lake endemic 77.4 54.7 35.3 244
Coast endemic 75.8 58.1 42.8 101
Semi-arid, seasonal 40.2 28.6 16.0 259
Low risk 38.2 22.9 12.9 379
Education
No education 44.2 31.6 20.8 167
Primary incomplete 55.6 40.3 22.6 187
Primary complete 57.5 39.2 25.0 404
Secondary+ 45.8 30.2 19.6 511
Wealth quintile
Lowest 51.7 38.7 24.1 300
Second 54.8 35.5 21.8 271
Middle 57.3 40.2 25.8 224
Fourth 45.3 29.1 15.8 231
Highest 44.3 29.2 21.5 242
Total 50.8 34.7 21.9 1,268
1
Received the specified number of doses of SP/Fansidar, at least one of which was received
during an ANC visit.
Table 4.3 presents information on the use of IPTp solely in the coast and lake endemic zones
where IPTp is recommended by the Kenya National Malaria Strategy. Overall, taking both zones into
consideration, 77 percent of women who gave birth in the 2 years prior to the survey received at least
one dose of SP, 56 percent received two or more doses, and 38 percent received the currently
recommended 3 doses or more. Considering the coast and lake zones separately, Table 4.3 shows
women were somewhat more likely to have received SP in the coast endemic zone than in the lake
endemic zone. The largest differential between the two zones was in the proportion of pregnant
women who had received at least three doses: 43 percent in the coast zone compared with 35
percent in the lake zone.
Malaria in Pregnancy • 51